Publications by authors named "Sara Hingtgen"
Background: Cystic fibrosis (CF) is a genetic disease associated with lung disease characterized by chronic pulmonary infection, increasingly caused by multiple drug-resistant pathogens after repeated antibiotic exposure, limiting antibiotic treatment options. Bacteriophages can provide a pathogen-specific bactericidal treatment used with antibiotics to improve microbiologic and clinical outcomes in CF.
Methods: Achromobacter species isolates from sputum of a chronically infected person with CF, were assessed for susceptibility to bacteriophages: 2 highly active, purified bacteriophages were administered intravenously every 8 hours, in conjunction with a 14-day piperacillin/tazobactam course for CF exacerbation.
Article Synopsis
- The study aimed to evaluate how renal function affects the clearance of meropenem in children with sepsis during their first two days in the PICU, and to measure the risk of insufficient drug exposure due to increased renal clearance.
- Researchers analyzed data from patients treated with meropenem at Rady Children's Hospital from 2015-2017, using a pharmacokinetic model to estimate drug exposure and effectiveness against pathogens.
- Results showed that nearly 50% of patients had increased renal clearance, leading to a significant risk of not achieving therapeutic levels of meropenem, indicating that higher doses may be necessary for effective treatment in the early stages of PICU care.
Background: Single-dose pharmacokinetics (PK) and safety of ceftaroline fosamil with population pharmacokinetic/pharmacodynamic (PK/PD) modeling for staphylococcal pneumonia was performed in children with CF.
Methods: Subjects between 6 and 18 years old were evaluated in this phase 1, open-label, single-dose, prospective study using 10 mg/kg (up to 600 mg). Non-compartmental analysis and population-based PK analyses with Monte Carlo simulation (for doses 8-20 mg/kg every 8 h, infused over 1-4 h) were conducted.